logo-loader
viewFaron Pharmaceuticals Ltd

Faron Pharma in talks to find partner for lead cancer drug

Clevegen is one of two drug candidates being developed by Faron. The other is Traumakine for a condition called acute respiratory distress

Faron Pharmaceuticals Ltd -

Faron Pharmaceuticals Ltd (LON:FARN) said discussions to find a commercial partner for its cancer immunotherapy continue.

In an update alongside its interim results, the drug developer said it is looking for a collaborator that will support and expand the clinical development Clevegen as well as assess its potential in combination with existing drugs.

An early-stage study of the potential treatment, called MATINS, has established a maximum tolerated level for the formulation. Partial responders to the medication were observed.

Manufacturing is underway to produce drugs for the second part of the MATINS study.

One of two drug candidates

Clevegen is one of two drug candidates being developed by Faron.

The other is Traumakine for a condition called acute respiratory distress (ARDS).

Faron said a third-party was likely to fund a second phase III trial on the treatment.

This new late-stage clinical evaluation would address the issue around steroid use in patients with the life-threatening condition.

New study design 

"It has become clear that Traumakine's development requires a study design which would avoid concomitant corticosteroid use,” Markku Jalkanen, the firm’s chief executive.

“Faron's solution is a design which would allow corticosteroid use within the standard of care arm but never in combination with Traumakine.

“As soon as the company receives feedback for this new design, we will finalise plans to allow us to progress third party funding discussions.

“The unmet medical need among these patients is significant and the widespread use of corticosteroids for ARDS and multi-organ failures requires serious re-consideration.”

In common with most drug developers investing in R&D, the company was loss-making. The deficit was €6.3mln. Cash at the period-end was €2.9mln.

Quick facts: Faron Pharmaceuticals Ltd

Price: 238.975 GBX

AIM:FARN
Market: AIM
Market Cap: £103.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Faron Pharmaceuticals makes 'groundbreaking discovery' in its MATINS trial

Faron Pharmaceuticals Oy (LON:FARN) (FIRSTNORTH:FARON) CEO Dr Markku Jalkanen speaks to Proactive London's Andrew Scott after updating on its phase I/II MATINS trial of Clevegen. He says it's been encouraging to discover that Clevegen can ‘down’ regulate a range of checkpoints that affect the...

on 12/12/19

2 min read